{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:22:31Z","timestamp":1788013351695,"version":"build-2784847793"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T00:00:00Z","timestamp":1525046400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00430","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T00:25:55Z","timestamp":1525047955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Jie-Li","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Hang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Inter-Groupe Francophone du: maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2008-03-145235","article-title":"Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jnci\/81.2.107","article-title":"Publication bias and dissemination of clinical research.","volume":"81","author":"Begg","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias.","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA.","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000471839","article-title":"Bortezomib, thalidomide, and dexamethasone (VTD) induction results in better overall survival than adriamycin, thalidomide, and dexamethasone (ATD) induction in previously untreated myeloma patients eligible for transplants.","volume":"137","author":"Chen","year":"2017","journal-title":"Acta Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2147\/CMAR.S117477","article-title":"Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.","volume":"9","author":"Chen","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/sim.4780131308","article-title":"Interim analysis: the alpha spending function approach.","volume":"13","author":"DeMets","year":"1994","journal-title":"Stat. Med."},{"key":"B11","first-page":"3073","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.","volume":"7","author":"Gao","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"B14","article-title":"\u201cLenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study,\u201d in","author":"Jackson","year":"2016","journal-title":"Proceedings of the 58th Annual Meeting of American Society of Hematology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2147\/ott.s84828","article-title":"Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials.","volume":"8","author":"Liu","year":"2015","journal-title":"Onco Targets Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3324\/haematol.2009.020586","article-title":"Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.","volume":"95","author":"Ludwig","year":"2010","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ajh.23274","article-title":"Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.","volume":"87","author":"Maiolino","year":"2012","journal-title":"Am. J. Hematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/asheducation-2016.1.504","article-title":"Role of stem cell transplant and maintenance therapy in plasma cell disorders.","volume":"2016","author":"McCarthy","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/jco.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis.","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jclinepi.2012.11.007","article-title":"Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error.","volume":"66","author":"Miladinovic","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/bjh.14780","article-title":"Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.","volume":"179","author":"Moreau","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11899-016-0310-9","article-title":"Consolidation and maintenance therapies for newly diagnosed multiple myeloma in the Era of novel agents.","volume":"11","author":"Nathwani","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2141.2008.07495.x","article-title":"Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.","volume":"144","author":"Offidani","year":"2009","journal-title":"Br. J. Haematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma.","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial.","volume":"31","author":"Rosinol","year":"2017","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool.","volume":"3","author":"Salanti","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"B35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.23","article-title":"Posttransplant maintenance therapy in multiple myeloma: the changing landscape.","volume":"7","author":"Sengsayadeth","year":"2017","journal-title":"Blood Cancer J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the national cancer institute of Canada clinicals trials group myeloma 10 trial.","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20170304","article-title":"Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.","volume":"37","author":"Sun","year":"2017","journal-title":"Biosci. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.clml.2017.02.010","article-title":"Multiple myeloma: clinical updates from the American society of hematology annual meeting 2016.","volume":"17","author":"Terpos","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B41","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions.","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv342","article-title":"Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review.","volume":"108","author":"Wang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.","volume":"28","author":"Wijermans","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072635","article-title":"Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials.","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review.","volume":"8","author":"Zeng","year":"2015","journal-title":"J. Evid. Based Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/CMAR.S138932","article-title":"Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.","volume":"9","author":"Zeng","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T00:25:55Z","timestamp":1525047955000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2018.00430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":48,"alternative-id":["10.3389\/fphar.2018.00430"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00430","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,30]]},"article-number":"430"}}